Understanding Xylazine: The Emerging Threat in Substance Abuse and How Passages Malibu Can Help

Understanding Xylazine: The Emerging Threat in Substance Abuse and How Passages Malibu Can Help

Published February 2024

In recent years, the substance abuse landscape has seen the emergence of new threats that pose significant challenges to public health. Among these, Xylazine, a non-opioid sedative used in veterinary medicine, has increasingly been found as an adulterant in illicit drug supplies. This development underscores the importance of staying informed about emerging substances and seeking effective treatment options like those provided by Passages Malibu.

What is Xylazine?

Xylazine, known colloquially as “tranq,” is approved for veterinary use as a sedative, analgesic, and muscle relaxant. However, its unauthorized use in humans can lead to severe health risks, including respiratory depression, bradycardia, hypotension, and even fatal outcomes when combined with opioids or other depressants.

The Rise of Xylazine in Illicit Drug Markets

Xylazine has been increasingly detected in illicit drug samples, especially those containing fentanyl and heroin. Its addition intensifies the drugs’ sedative effects, raising the risk of overdose and complicating the treatment of substance use disorders. The presence of Xylazine in the drug supply is particularly concerning because it does not respond to naloxone, the standard treatment for opioid overdoses.